Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan, Vincristine, Temozolomide ± Anlotinib in Pediatric Relapsed/Refractory Solid Tumors
NCT07444918Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Lipid-based Nanoparticles, Nucleic Acid-Directed Small Molecules, Covalent Small Molecules
01
Overview
A Phase 2 trial of nanoliposomal irinotecan, vincristine, temozolomide, anlotinib in malignant solid tumor, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecanvincristinetemozolomideanlotinib
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07444918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444918.